Adaptimmune Therapeutics PLC
ADAPY- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001621227
No open-market purchases or sales by Adaptimmune Therapeutics PLC insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Adaptimmune Therapeutics PLC changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Of which not filed for Q3 2022 | Q3 2022 | Change |
|---|---|---|---|---|
| Holders | 77 | 1 | 68 | −8 |
| Shares | 114.7M | 121 | 113.9M | −872.6K (−0.8%) |
| Value | $195.1M | $206 | $122.4M | −$72.6M (−37.2%) |
1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (10)
Institutions that held Adaptimmune Therapeutics PLC at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Gsa Capital Partners LLP | 381,043 | $410.0K | 0.05% |
| Kettle Hill Capital Management, LLC | 253,134 | $272.0K | 0.06% |
| SEI Investments Co | 31,287 | $34.0K | 0.00% |
| HBK Sorce Advisory LLC | 35,000 | $32.0K | 0.00% |
| RFG Advisory, LLC | 10,000 | $21.0K | 0.00% |
| Creative Planning | 12,878 | $14.0K | 0.00% |
| Narwhal Capital Management | 10,344 | $11.0K | 0.00% |
| Quadrant Capital Group LLC | 1,046 | $1.00K | 0.00% |
| Aquatic Capital Management LLC | 1,100 | $1.00K | 0.00% |
| China Universal Asset Management Co., Ltd. | 1,345 | $1.00K | 0.00% |
Sold out (18)
Institutions that held Adaptimmune Therapeutics PLC at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Point72 Asset Management, L.P. | 647,008 | $1.10M |
| Rafferty Asset Management, LLC | 217,123 | $369.0K |
| Susquehanna International Group, LLP | 134,912 | $229.0K |
| Erste Asset Management GmbH | 90,000 | $153.9K |
| Jane Street Group, LLC | 44,086 | $75.0K |
| Qube Research & Technologies Ltd | 43,966 | $75.0K |
| Crestline Management, LP | 39,489 | $67.0K |
| Caxton Associates LP | 23,034 | $39.0K |
| HRT Financial LP | 21,091 | $35.0K |
| Tudor Investment Corp Et Al | 15,232 | $26.0K |
| Engineers Gate Manager LP | 14,294 | $24.0K |
| Itau Unibanco Holding S.A. | 7,434 | $13.0K |
| Vectors Research Management, LLC | 7,000 | $12.0K |
| Cubist Systematic Strategies, LLC | 2,094 | $4.00K |
| Quantbot Technologies LP | 2,000 | $3.00K |
| Blue Bell Private Wealth Management, LLC | 759 | $1.00K |
| Joseph P. Lucia & Associates, LLC | 375 | $1.00K |
| Cutler Group LP | 400 | $0 |
Not filed for Q3 2022 yet (1)
Institutions that held Adaptimmune Therapeutics PLC at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Exane Derivatives | 121 | $206 |